| 8.6711 1.361 (18.62%) | 10-09 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.23 |
1-year : | 11.95 |
| Resists | First : | 8.76 |
Second : | 10.23 |
| Pivot price | 7.17 |
|||
| Supports | First : | 7.08 |
Second : | 6.05 |
| MAs | MA(5) : | 7.58 |
MA(20) : | 6.99 |
| MA(100) : | 7.39 |
MA(250) : | 5.52 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 80.9 |
D(3) : | 79.1 |
| RSI | RSI(14): 69.7 |
|||
| 52-week | High : | 11.4 | Low : | 1.73 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SGMT ] has closed Bollinger Bands are 27% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.84 - 7.88 | 7.88 - 7.9 |
| Low: | 7.06 - 7.11 | 7.11 - 7.14 |
| Close: | 7.24 - 7.31 | 7.31 - 7.36 |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Thu, 09 Oct 2025
Sagimet Biosciences' (SGMT) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Thu, 09 Oct 2025
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Tue, 07 Oct 2025
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha
Tue, 07 Oct 2025
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - GlobeNewswire
Tue, 07 Oct 2025
Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative
Tue, 07 Oct 2025
≥2‑Stage Fibrosis Improvement: Sagimet denifanstat data to be presented at AASLD 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 29.1 (%) |
| Shares Short | 3,110 (K) |
| Shares Short P.Month | 2,800 (K) |
| EPS | -1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.7 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -4.67 |
| PEG Ratio | 0 |
| Price to Book value | 2.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|